Celgene Co. (CELG) Director Sells $877,177.50 in Stock

Celgene Co. (NASDAQ:CELG) Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $94.83, for a total value of $877,177.50. Following the completion of the sale, the director now owns 94,801 shares of the company’s stock, valued at approximately $8,989,978.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Gilla Kaplan also recently made the following trade(s):

  • On Thursday, February 15th, Gilla Kaplan sold 9,250 shares of Celgene stock. The shares were sold at an average price of $95.99, for a total value of $887,907.50.

Celgene Co. (CELG) opened at $93.78 on Friday. The stock has a market capitalization of $70,621.77, a price-to-earnings ratio of 13.69, a PEG ratio of 0.66 and a beta of 1.49. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. Celgene Co. has a 12-month low of $88.32 and a 12-month high of $147.17.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. The business had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s quarterly revenue was up 16.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.61 earnings per share. equities research analysts anticipate that Celgene Co. will post 7.68 EPS for the current year.

Celgene declared that its Board of Directors has initiated a share repurchase program on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Hedge funds have recently modified their holdings of the company. Thompson Davis & CO. Inc. increased its position in shares of Celgene by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares in the last quarter. Virtue Capital Management LLC acquired a new position in shares of Celgene in the 4th quarter valued at $101,000. Arcadia Investment Management Corp MI increased its position in shares of Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares during the period. Robecosam AG acquired a new position in shares of Celgene in the 3rd quarter valued at $114,000. Finally, Guidant Wealth Advisors acquired a new position in shares of Celgene in the 3rd quarter valued at $119,000. 77.84% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently issued reports on CELG. Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a report on Tuesday, January 23rd. UBS Group lowered Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price target for the company. in a report on Thursday, October 26th. BMO Capital Markets lowered their price target on Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Barclays reiterated an “equal weight” rating and issued a $105.00 price target (down previously from $135.00) on shares of Celgene in a report on Friday, October 27th. Finally, Deutsche Bank began coverage on Celgene in a report on Tuesday, December 12th. They issued a “hold” rating and a $114.00 price target for the company. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the stock. Celgene presently has a consensus rating of “Buy” and a consensus target price of $130.25.

WARNING: This story was first posted by BBNS and is the property of of BBNS. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://baseballnewssource.com/markets/celgene-co-celg-director-sells-877177-50-in-stock/1907627.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.